相关实验视频

Updated: Jul 22, 2026

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Polymalic Acid-based Nano Biopolymers for Targeting of Multiple Tumor Markers: An Opportunity for Personalized Medicine?

Published on: June 13, 2014

AXL - - 一个在抵抗HER2封锁的新参与者

Anna Adam-Artigues¹, Enrique J Arenas², Joaquín Arribas³

¹INCLIVA Biomedical Research Institute, Spain.

Cancer treatment reviews

|October 21, 2023

概括

阳性HER2癌症可能会对抗HER2疗法产生耐药性. 与HER2一起准AXL,一个受体氨酸激酶,在克服这种耐药性和改善患者结果方面显示出希望.

科学领域:

在瘤学瘤学.
分子生物学分子生物学
癌症治疗方法癌症治疗方法

背景情况:

人体表皮生长因子受体2 (HER2) 是几个固体瘤的关键驱动因素,包括乳腺癌,食道癌和胃癌.
过度表达HER2与侵袭性疾病和不良预后有关,有针对性的抗HER2疗法是治疗的标准.
对抗HER2药物的治疗耐药性是一个重大的临床挑战,需要新的治疗策略.

研究的目的:

研究AXL的作用,一个受体氨酸激酶,在调解抗HER2疗法的耐药性.
探索AXL和HER2共同向的潜力,作为克服治疗耐药性的战略.
评估AXL作为HER2-阳性癌症的预后和预测生物标志物.

主要方法:

对研究抗HER2耐药性的机制的临床前研究的审查.
分析AXL信号通路及其与HER2的交叉通话.
在克服耐药性的AXL抑制的体外和体内模型的评估.

主要成果:

AXL上调是抗HER2治疗耐药性的关键机制,促进癌细胞的增殖,生存,迁移,入侵和血管生成.
AXL信号,特别是与间酶体表型相结合,赋予了对化疗和向治疗的耐药性.
临床前数据表明,AXL抑制可以恢复乳腺癌,食道癌和胃癌中对HER2阻塞的敏感性.
在HER2阳性乳腺癌中,AXL作为预后和预测生物标志物具有显著的潜力.

结论:

同时准AXL和HER2是一个有希望的治疗策略,以克服对HER2向疗法的耐药性.
抑制AXL可能是一种有价值的方法,以重新敏感化对HER2向治疗耐药的瘤.
作为HER2驱动癌症中的生物标志物和治疗标,AXL具有翻译相关性.

关键词:

一个AXLL.癌症癌症癌症癌症这是一种HER2疾病.电阻电阻电阻电阻电阻电阻

更多相关视频

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure

Published on: August 11, 2017

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

相关概念视频

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

Treatment Resistent Cancers

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...